Assessment of the Hemophagocytic Lymphohistiocytosis HScore in Patients With Coronavirus Disease 2019
Assessment of the Hemophagocytic Lymphohistiocytosis HScore in Patients With Coronavirus Disease 2019
复制标题
DOI：
10.1093/cid/ciaa1463
复制
发表时间：
2021-11-01
影响因子：
11.8
通讯作者：
Singh, Animesh
中科院分区：
文献类型：
--
作者：
Clark, Kristina E. N.;Nevin, William D.;Singh, Animesh
中到重度冠状病毒病2019(新冠肺炎)的临床表现与继发性噬血细胞淋巴组织细胞增生症(HLH)在临床和分子炎症反应上都有相似之处。我们没有发现证据支持使用为高血压患者设计的风险评分方法对新冠肺炎患者进行风险分层的效用。
The clinical manifestation of moderate to severe coronavirus disease 2019 (COVID-19) has parallels to secondary hemophagocytic lymphohistiocytosis (HLH) both clinically and based on molecular inflammatory response. We found no evidence to support the utility of risk-stratifying COVID-19 patients using risk scoring methodology designed for HLH.